genuine question about phase 2 that I am slightly embarrassed to ask
genuine question about phase 2 that I am slightly embarrassed to ask. If this has been answered properly somewhere, link me and I will delete.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.